RPL9 (Ribosomal Protein L9) encodes a ribosomal protein component of the 60S large ribosomal subunit. While primarily known for its role in protein synthesis as part of the ribosome, RPL9 has emerging connections to disease processes including Diamond-Blackfan anemia (DBA), various cancers, and inflammatory responses[@lezzerini2020][@jeon2024]. Notably, RPL9 has been shown to have extraribosomal functions including anti-apoptotic activity and regulation of inflammatory signaling, positioning it at the intersection of ribosomopathies, oncology, and immunology[@eid2014][@watanabe2022].
| Full Name | Ribosomal Protein L9 |
|---|
| Gene Symbol | RPL9 |
|---|
| Chromosomal Location | 4p15.2 |
|---|
| NCBI Gene ID | 6133 |
|---|
| OMIM | 604174 |
|---|
| Ensembl ID | ENSG00000163682 |
|---|
| UniProt ID | P32969 |
|---|
| Protein Length | 192 amino acids |
|---|
| Protein Molecular Weight | ~22 kDa |
|---|
| Associated Diseases | [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Ribosomopathies](/diseases/ribosomopathies), [Various Cancers](/diseases/cancer), Inflammatory Disorders |
|---|
RPL9 is a component of the 60S large ribosomal subunit, contributing to the structural integrity and functional capacity of the ribosome[@wool1979][@mcnally2023]. As part of the translation machinery, RPL9 participates in:
- Protein synthesis: Contributes to peptide bond formation at the peptidyl transferase center
- Ribosome assembly: Essential for proper 60S subunit biogenesis
- rRNA interaction: Interacts with 28S rRNA to stabilize the large subunit
- Translation termination: Participates in the release factor binding site
RPL9 has several distinctive structural features[@mcnally2023]:
- N-terminal domain: Contains RNA-binding regions
- Central region: Involved in protein-protein interactions
- Surface localization: Positioned to interact with both ribosomal proteins and extraribosomal factors
Beyond its ribosomal role, RPL9 has several important extraribosomal functions:
Anti-apoptotic Activity:
- RPL9 can suppress Bax-mediated apoptosis[@eid2014]
- This function is conserved from yeast to humans
- Provides a cell survival advantage under stress conditions
- May contribute to cancer cell survival
Inflammatory Response Regulation:
- RPL9 regulates damage-associated molecular pattern (DAMP) molecules[@watanabe2022]
- Modulates inflammatory signaling pathways
- May play a role in immune response to cellular stress
Cancer Progression:
- RPL9 maintains cancer stem cell properties via ID-1[@jeon2024]
- Promotes tumor growth through exosome-mediated miRNA shuttling[@li2024]
- Knockdown inhibits tumor growth via Id-1/NF-κB inactivation[@baik2016]
RPL9 mutations cause Diamond-Blackfan anemia, a pure red cell aplasia characterized by failure of red blood cell production[@lezzerini2020][@narla2010]. RPL9 mutations represent a smaller percentage of DBA cases:
Clinical Phenotype:
- Macrocytic anemia presenting in infancy or early childhood
- Growth retardation
- Variable skeletal anomalies
- Predisposition to other hematologic disorders
Molecular Mechanism:
- RPL9 haploinsufficiency leads to impaired 60S biogenesis
- Ribosomal stress activates p53 through MDM2 inhibition
- Erythroid precursors are particularly sensitive to ribosomal stress
- p53-mediated apoptosis reduces erythroid progenitor pool
¶ Cancer Susceptibility and Progression
RPL9 has complex roles in cancer biology[@jeon2024][@li2024][@baik2016]:
Oncogenic Functions:
- RPL9 acts as an oncogene in hepatocellular carcinoma through exosome-mediated miRNA transport
- Maintains cancer stem cell properties via ID-1 dependent mechanism
- Promotes colorectal carcinoma growth through Id-1/NF-κB signaling
Tumor Suppressor Functions:
- RPL9 can suppress Bax-mediated apoptosis (potentially anti-oncogenic)
- Activates p53 signaling pathway in B-cell acute lymphoblastic leukemia[@li2025]
- May have context-dependent functions
Therapeutic Implications:
- RPL9 is a potential therapeutic target for B-ALL through p53 activation
- Knockdown of RPL9 inhibits tumor growth in various cancers
- Exosome-mediated RPL9 function provides novel therapeutic target
While not directly implicated in neurodegenerative diseases, RPL38 biology informs our understanding of neurodegeneration[@zhou2022]:
Ribosomal Stress and Neuronal Death:
- Chronic ribosomal stress can lead to p53 activation in neurons
- p53 activation can trigger neuronal apoptosis
- Ribosomal dysfunction is observed in Alzheimer's, Parkinson's, and ALS
Inflammatory Response:
- RPL9 regulates inflammatory signaling
- Neuroinflammation is a key feature of neurodegenerative diseases
- Understanding RPL9's role may inform inflammatory mechanisms in neurodegeneration
RPL9 is ubiquitously expressed across all tissues, with particularly high expression in:
- Bone marrow (hematopoietic cells)
- Rapidly proliferating cells
- Brain tissue, particularly in neurons
- Liver and gastrointestinal tract
The protein localizes primarily to the cytoplasm where it functions in ribosomal complexes. During cellular stress, RPL9 can accumulate in free pools and function in extraribosomal roles.
RPL9 expression in the nervous system:
- Expressed in various brain regions
- Important for neuronal protein synthesis
- Required for synaptic function
- May be affected in neurodegenerative conditions
In cancer contexts:
- Overexpression in multiple cancer types
- Associated with cancer stem cell properties
- Prognostic marker in some cancers
- Therapeutic target potential
Therapeutic approaches include:
- Corticosteroids: First-line treatment; mechanism involves translational enhancement
- L-leucine: Amino acid that improves translation efficiency
- Gene therapy: Autologous hematopoietic stem cell gene addition
- Supportive care: Transfusions for steroid-non-responsive patients
Understanding RPL9 has therapeutic implications:
- Targeted therapy: RPL9 is a potential target for B-ALL treatment
- Exosome inhibition: Blocking RPL9-mediated miRNA transport
- ID-1 targeting: Downstream pathway inhibition
¶ Inflammation and Immune Disorders
RPL9's role in DAMP regulation suggests:
- Anti-inflammatory therapy: Modulating RPL9 function
- Autoimmune conditions: Understanding RPL9's immunological role
¶ Mermaid Diagram: RPL9 in Ribosomal Function and Disease
flowchart TD
subgraph Normal_Ribosomal_Function
A["RPL9 Gene<br/>Transcription"] --> B["mRNA<br/>Translation"]
B --> C["RPL9 Protein<br/>Synthesis"]
C --> D["60S Subunit<br/>Assembly"]
D --> E["80S Ribosome<br/>Formation"]
E --> F["Protein<br/>Synthesis"]
F --> G["Cell<br/>Proliferation"]
end
subgraph Extraribosomal_Functions
H["Free RPL9<br/>Accumulation"] --> I["Anti-apoptotic<br/>Function"]
I --> J["Bax<br/>Suppression"]
J --> K["Cell<br/>Survival"]
H --> L["Inflammatory<br/>Regulation"]
L --> M["DAMP<br/>Signaling"]
M --> N["Immune<br/>Response"]
end
subgraph Disease_Connections
O["RPL9<br/>Mutation"] --> P["Ribosomal<br/>Stress"]
P --> Q["Impaired 60S<br/>Biogenesis"]
Q --> R["Translational<br/>Defect"]
R --> S["Selective<br/>Cytopenia"]
T["RPL9<br/>Overexpression"] --> U["Oncogenic<br/>Function"]
U --> V["ID-1<br/>Signaling"]
V --> W["Tumor<br/>Growth"]
T --> X["Exosome<br/>Function"]
X --> Y["miRNA<br/>Transport"]
Y --> Z["Cancer<br/>Progression"]
end
subgraph Neurodegeneration_Link
P --> AA["Chronic<br/>Ribosomal Stress"]
AA --> BB["Neuronal p53<br/>Activation"]
BB --> CC["Neuronal<br/>Apoptosis"]
CC --> DD["Neurodegeneration"]
end
style O fill:#ffcdd2
style S fill:#ffcdd2
style W fill:#ef9a9a
style Z fill:#ef9a9a
style DD fill:#ef9a9a
- Lezzerini et al., RPL9 variants impair ribosome function (2020)
- Devis et al., Dosage Sensitivity of RPL9 in Plants (2015)
- Hou et al., Overexpression of RPL9 in giant panda (2011)
- Jeon et al., RPL9 maintains cancer stemness (2024)
- Li et al., RPL9 as therapeutic target for B-ALL (2025)
- Watanabe et al., RPL9 regulates DAMPs (2022)
- Tian et al., UNR regulates RPL9 in glioma (2018)
- Li et al., RPL9 shuttles miRNAs via exosomes (2024)
- Baik et al., RPL9 knockdown inhibits colorectal carcinoma (2016)
- Eid et al., RPL9 is a Bax suppressor (2014)
- Wool, Structure and evolution of ribosomal proteins (1979)
- McNally et al., Structure and function of RPL9 (2023)
- Narla & Ebert, Ribosomopathies (2010)
- Mills & Green, Ribosomopathies (2017)
- Zhou et al., Ribosomal stress and neurodegeneration (2022)